- M.D.: Columbia College of Physicians and Surgeons,
- Residency in Neurology at Mount Sinai Medical Center, New York
- Residency in Internal Medicine at Jacobi Medical Center, Bronx, NY
- Rheumatology Fellowship, Johns Hopkins University School of Medicine
- Masters in Clinical Investigation , Johns Hopkins Bloomberg School of Public Health
Dr. Julius Birnbaum is Assistant Professor of Medicine in the Division of Rheumatology. He holds a joint appointment in the Department of Neurology, and is Associate Director of the Johns Hopkins Jerome L. Greene Sjogren’s Syndrome Center. Dr. Birnbaum is a graduate of Columbia College of Physicians & Surgeons. He completed a neurology residency at Mount Sinai Medical Center, and then pursued an internal medicine residency at Jacobi Medical Center. Thereafter, Dr. Birnbaum obtained fellowship training in rheumatology at Johns Hopkins, during which time he completed a Masters in Health Sciences degree in Clinical Investigation at the Bloomberg School of Public Health.
The overall goal of Dr. Birnbaum’s research is to define etiopathogenic mechanisms associated with neurological complications of systemic rheumatic diseases. A unifying theme of his research is that meticulous identification of neurological phenotypes can be harnessed to identify both in vitro and in vivo biomarkers A recent example is the identification of unique phenotypes of lupus demyelinating syndromes which were associated with discriminating antibody specificities, neuroimaging findings, and cerebrospinal fluid abnormalities.
A current focus is to identify biomarkers associated with neuropathic pain in affected patients with Sjogren’s syndrome. Candidate biomarkers which are now being investigated include known antibody specificities, novel anti-neuronal antibody specificities, in vitro approaches (i.e., neurotoxicity assays), in vivo neuroimaging studies of peripheral nerve elements, and Quantitative Sensory Testing to identify markers of centrally-sensitized pain. Other research areas include the identification of biomarkers which can distinguish demyelinating disorders as occurring due to a primary rheumatic disease versus a primary demyelinating disorder (i.e., Multiple Sclerosis).